The TEL-AML1 Fusion Accompanied by Loss of the Untranslocated TEL Allele in B-Precursor Acute Lymphoblastic Leukaemia of Childhood

References

• Romana S. P., Poirel H., Leconiat M., Flexor M-A., MauchauffÉ M., Jonveaux P., Macintyre E. A., Berger R., Bernard O. A. High frequency of t(12;21) in childhood B-line-age acute lymphoblastic leukemia. Blood 1995; 86: 4263
   PubMed Web of Science ®Google Scholar
• Shurtleff S. A., Buijs A., Behm F. G., Rubnitz J. E., Raimondi S. C., Hancock M. L., Chan G.C.F., Pui C. H., Grosveld G., Downing J. R. TEL-AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985
   PubMed Web of Science ®Google Scholar
• Liang D. C., Chou T. B., Chen J. S., Shurtleff S. A., Rubnitz J. E., Downing J. R., Pui C. H., Shih L. Y. High incidence of TEL-AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan. Leukemia 1996; 10: 991
   PubMed Web of Science ®Google Scholar
• Raynaud S., CavÉ H., Baens M., Bastard C., Cacheux V., Grosgeorge J., Guidal-Giroux C., Guo C., Vilmer E., Marynen P., Grandchamp B. The 12;21 translocation involving TEL and deletion of the other TEL allele: Two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996; 87: 2891
   PubMed Web of Science ®Google Scholar
• Borkhardt A., Cazzangia G., Ludwig W-D., Mangioni S., Burci L., Schrappe M., Valsecchi M. G., Riehm H., Lampert F., Basso G., Masera G., Harbott J., Biondi A. Does the TEL-AML1 expression define a subgroup of good prognosis? The results of the German (BFM) and Italian (AIEOP) ALL study group. Blood 1996; 88: 451a
   Google Scholar
• McLean T. W., Ringold S., Neuberg D., Stegmaier K., Tantra-Vahi R., Ritz J., Koeffler H. P., Takeuchi S., Janssen J.W.G., Seriu T., Bartram C. R., Sallan S. E., Gilliland D. G., Golub T. R. TEL/AML-1 dimerizes and is associated with a favourable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252
   PubMed Web of Science ®Google Scholar
• Golub T. R., Barker G. F., Bohlander S. K., Hiebert S. W., Ward D. C., Bray-Ward P., Morgan E., Raimondi S. C., Rowley J. D., Gilliland D. G. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 1995; 92: 4917
   PubMed Web of Science ®Google Scholar
• Romana S.R, Mauchauffe M., Le Coniat M., Chumakov I., Le Pasier D., Berger R., Bernard O. A. The t(12;21) of acute lymphoblastic leukemia results in a TEL-AML1 gene fusion. Blood 1995; 85: 3662
   PubMed Web of Science ®Google Scholar
• Raimondi S. C., Williams D. L., Callihan T., Peiper S., Rivera G. K., Murphy S. B. Nonrandom involvement of the 12p12 breakpoint in chromosome abnormalities of childhood acute lymphoblastic leukemia. Blood 1986; 68: 69
   PubMed Web of Science ®Google Scholar
• Mitelman F. Catalog of chromosome aberrations in cancer. 5^th ed. Wiley-Liss, New York 1994
   Google Scholar
• Romana S. P., Le Coniat M., Poirel H., Marynen P., Bernard O. A., Berger R. Deletion of the short arm of chromosome 12 is a secondary event in acute lymphoblastic leukemia with t(12;21). Leukemia 1996; 10: 167
   PubMed Web of Science ®Google Scholar
• Cave H., Cacheux V., Raynaud S., Brunie G., Bakkus M., Cochaux P., Preudhomme C., LaÏ J.L., Vilmer E., Grand-Champ B. ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. Leukemia 1997; 11: 1459
   PubMed Web of Science ®Google Scholar
• Kempski H., Chalker J., Chessells J., Start N., Brickell P., Webb J., Macdonald-Clink J., Reeves B. An investigation of the t(12;21) rearrangement in children with B-precursor acute lymphoblastic leukaemia using cytogenetic and molecular methods. Brit. J. Haemat. 1999; 105: 684
   PubMed Web of Science ®Google Scholar
• Golub T. R., Barker G. F., Lovett M., Gilliland D. G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307
   PubMed Web of Science ®Google Scholar
• Ghysdael J. Les régulateurs transcriptionnels de la famille Ets et leur implication dans les processus physi-ologiques normaux et la cancérogénèse. Path. Biol. 1995; 43: 202
   PubMedGoogle Scholar
• Bernard O. A., Romana S.R, Poirel H., Berger R. Molecular cytogenetics of t(12;21)(p13;q22). Leuk. Lymph. 1996; 23: 459
   PubMed Web of Science ®Google Scholar
• Aissani B., Bonan C., Baccichet A., Sinnett D. Childhood acute lymphoblastic leukemia: Is there a tumor suppressor gene in chromosome 12p12.3?. Leuk. Lymph. 1999; 34: 231
   PubMed Web of Science ®Google Scholar
• Rubnitz J. E., Pui C-H., Downing J. R. The role of TEL fusion genes in pediatric leukemias. Leukemia 1999; 13: 6
   PubMed Web of Science ®Google Scholar
• Baens M., Peeters P., Guo C., Aerssens J., Marynen P. Genomic organization of TEL: the human ETS-variant gene 6. Genome Res. 1996; 6: 404
   PubMed Web of Science ®Google Scholar
• Poirel H., Lacronique V., Mauchauffe M., Le Coniat M., Raffoux E., Daniel M-T., Erickson P., Drabkin H., Macleod R.A.F., Drexler H. G., Ghysdael J., Berger R., Bernard O. A. Analysis of TEL proteins in human leukemias. Oncogene 1998; 16: 2895
   PubMed Web of Science ®Google Scholar
• Wang L. C., Swat W., Fujiwara Y., Davidson I., Visvader J., Kuo F., Alt F. W., Gilliland D. G., Golub T. R., Orkin S. H. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 1998; 12: 2392
   PubMed Web of Science ®Google Scholar
• Meyers S., Downing J. R., Hiebert S. W. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol. Cell Biol. 1993; 13: 6336
   PubMed Web of Science ®Google Scholar
• Agape P., Gerard B., CavÉ H., Devaux I., Vilmer E., Lecomte M-C., Grandchamp B. Analysis of E7V6 and ETV6-AML1 proteins in acute lymphoblastic leukaemia. Brit. J. Haematol. 1997; 98: 234
   PubMed Web of Science ®Google Scholar
• Sasaki K., Yagi H., Branson R. T., Tominaga K., Matsunashi T., Deguchi K., Tani Y., Kishimoto T., Komori T. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc. Natl. Acad., Sci. USA 1996; 93: 12356
   Web of Science ®Google Scholar
• Shoemaker S. G., Hromas R., Kaushansky K. Transcriptional regulation of interleukin 3 gene expression in T lymphocytes. Proc. Natl. Acad. Sci. USA 1990; 87: 9650
   PubMed Web of Science ®Google Scholar
• Takahashi A., Satake M., Yamaguchi-Iwai Y., Bae S. C., Lu J., Maruyama M., Zhang Y. W., Oka H., Arai K., Ito Y. Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2. Blood 1995; 86: 607
   PubMed Web of Science ®Google Scholar
• Okuda T., Van Deursen J., Hiebert S. W., Grosveld G., Downing J. R. AML1, the target of multiple chromosomal translocation in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84: 321
   PubMed Web of Science ®Google Scholar
• Kim D-H., Moldwin R. L., Vignon C., Bohlander S. K., Suto Y., Giordano L., Gupta R., Fears S., Nucifora G., Rowley J. D., Smith S. D. TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. Blood 1996; 88: 785
   PubMed Web of Science ®Google Scholar
• Hiebert S. W., Sun W., Davis J. N., Golub T., Shurtleff S., Buijs A., Downing J. R., Grosveld G., Roussel M.F, Gilliland D. G., Lenny N., Meyers S. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol. Cell. Biol 1996; 16: 1349
   PubMed Web of Science ®Google Scholar
• Cayuela J. M., Baruchel A., Orange C., Madani A., Auclerc M. F., Daniel M. T., Schaison G., Sigaux F. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 1996; 88: 302
   PubMed Web of Science ®Google Scholar
• Golub T. R., Barker G.F, Stegmaier K., Gilliland D. G. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Curr. Top. Microbiol. Immunol. 1997; 220: 67
   PubMed Web of Science ®Google Scholar
• Knudson A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 1971; 68: 820
   PubMed Web of Science ®Google Scholar
• Vogelstein B., Kinzler K. W. The multistep nature of cancer. Trend. Genet. 1993; 9: 138
   PubMed Web of Science ®Google Scholar
• Takeuchi S., Bartram C. R., Seriu X., Miller C. W., Tobler A., Janssen J. W., Reiter A., Ludwig W.D, Zimmermann M., Schwaller J., Lee E., Miyoshi I, Koeffler H. P. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995; 86: 755
   PubMed Web of Science ®Google Scholar
• Baccichet A., Sinnett D. Frequent deletion of chromosome 12p12.3 in children with acute lymphoblastic leukaemia. Brit. J. Haematol. 1997; 99: 107
   PubMed Web of Science ®Google Scholar
• Kobayashi H., Montgomery K. T., Bohlander S. K., Adra C. N., Lim B. L., Kucherlapati R. S., Donis-Keller H., Holt M. S., Le Beau M.M., Rowley J. D. Fluorescence in situ hybridization mapping of translocations and deletions involving the short arm of human chromosome 12 in malignant hematologic diseases. Blood 1994; 84: 3473
   PubMed Web of Science ®Google Scholar
• Hoglund M., Johansson B., Pedersen-Bjergaard J., Marynen P., Mitelman F. Molecular characterisation of 12p abnormalities in hematologic malignancies: deletion of KIP1, rearrangement of TEL, and amplificaiton of CCND2. Blood 1996; 87: 324
   PubMed Web of Science ®Google Scholar
• Andreasson P., Johansson B., Arheden K., Billstrom R., Mitelman F., Hoglund M. Deletions of CDKN1B and ETV6 in acute myeloid leukemia and myelodysplastic syndromes without cytogenetic evidence of 12p abnormalities. Genes Chrom. Cancer 1997; 19: 77
   PubMed Web of Science ®Google Scholar
• Wiemels J. L., Ford A. M., Van Wering E.R., Postma A., Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 1999; 94: 1057
   PubMed Web of Science ®Google Scholar
• Nakao M., Yokota S., Horiike S., Taniwaki Y., Matsushita T., Fujimoto T., Misawa S. Detection and quantification of TEL-AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 1996; 10: 1463
   PubMed Web of Science ®Google Scholar
• Loh M. L., Silverman L. B., Young MX., Neuberg D., Golub T. R., Sallan S. E., Gilliland D. G. Incidence of TEL-AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998; 92: 4792
   PubMed Web of Science ®Google Scholar
• Seeger K., Adams H. P., Buchwald D., Beyermann B., Kre-Mens B., Niemeyer C., Ritter J., Schwabe D., Harms D., Schrappe M., Henze G. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. Blood 1998; 91: 1716
   PubMed Web of Science ®Google Scholar
• Rubnitz J. E., Behm EG., Wichlan D., Ryan C., Sandlund J. T., Ribeiro R. C., Rivera G. K., Hancock M. L., Relling M. V., Evans W. E., Pui C. H., Downing J. R. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia 1999; 13: 19
   PubMed Web of Science ®Google Scholar
• Zuna J., Hrusak O., Kalinova M., Muzikova K., Stary J., Trka J. TEL-AML1 positivity in childhood ALL: average or better prognosis? Czech Paediatric Haematology Working Group. Leukaemia 1999; 13: 22
   PubMed Web of Science ®Google Scholar
• Richards S., Burrett J., Hann I., Chessells J., Hill E., Bailey C. for the Medical Research Council Working Party on Childhood Leukaemia Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL x and UKALL XI. Leukemia 1998; 12: 1031
   PubMed Web of Science ®Google Scholar